Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders
Nikolai A. Podoltsev, Dennis Cooper(Yale Cancer Center), Iván Bustillo(Altru Health System), Yanhong Deng(Sun Yat-sen University), Bingnan Zhang(The University of Texas MD Anderson Cancer Center), Xiaopan Yao(Dana-Farber Cancer Institute)
Cited by 8
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456